Thinly traded Mesoblast Limited (NASDAQ:MESO) rockets 51% premarket on average volume in reaction to its announcement of
an 83% (n=10/12) survival rate in ventilator-dependent COVID-19
patients who were treated with its allogeneic mesenchymal stem cell
product candidate remestemcel-L within the first five days. Nine of the
10 were weaned off ventilator support after a median of 10 days, while
seven have been discharged from the hospital.
By comparison, 9% (n=38/445) of
ventilator-dependent COVID-19 patients at a major New York City hospital
who received standard-of-care treatment were able to discontinue
ventilator support. The survival rate was only 12% (n=38/320) in
ventilator-dependent COVID-19 patients at another major hospital in the
city.
A Phase 2/3 study is in process.
https://seekingalpha.com/news/3564093-mesoblast-cell-therapy-shows-significant-benefit-in-covidminus-19-patients
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.